Cyprumed GmbH

Cyprumed is a clinical-stage drug delivery company based in Innsbruck, Austria, developing proprietary technologies to make complex medicines suitable for oral administration. Its work focuses on therapeutic peptides, including GLP-1 and macrocyclic peptides, as well as injectable drugs in Biopharmaceutics Classification System Class IV, which can be challenging to deliver by mouth. The company offers three oral delivery platforms for intestinal and gastric peptide delivery and BCS Class IV compounds. These technologies are designed to improve bioavailability and reduce food effects, with tablet formulations intended for efficient production and scale-up while meeting key regulatory requirements.

Cyprumed works with organizations across the biopharmaceutical industry, from emerging biotechnology companies to major pharmaceutical firms, providing expertise and opportunities for collaboration in oral drug development. The company reports more than ten years of experience, proprietary technology, patent protection and freedom-to-operate considerations. Its platform is advancing through clinical development, including a Phase I trial initiated by MSD. Through its technology and partnerships, Cyprumed aims to help transform promising therapeutic compounds into high-quality oral drug products.